probing the influence of kukoamine A on interleukin-1 beta-evoked damage of chondrocytes and its possible mechanism. Interleukin-1 beta was used to induce human knee joint chondrocytes ... were used to treat…
activities in mammals. Yet, the effect and possible mechanism of bamboo leaf flavone on interleukin-1 beta-induced chondrocyte damage is still unclear. Methods interleukin-1 beta was used ... microRNA127-5p mimics were…
osteoarthritis and the potential mechanism of action. Primary rat chondrocytes were treated with interleukin-1 beta and various concentrations of corilagin. Terminal deoxynucleotidyl transferase biotin-dUTP nick end…
treatment with aspirin, or any other non-steroidal anti-inflammatory drugs, colchicine, and corticosteroids. Interleukin-1 is a master proinflammatory cytokine existing in two isoforms ... metabolic syndromes, and…
synthesis and release of Interleukin-1 (IL-1) are finely regulated processes necessary for the initiation of an inflammatory response to injury. Release of IL-1α from injured cells
inflammatory Interleukin-1 receptor antagonist (IL-1RN) gene polymorphism and high risk Helicobacter pylori virulence factors in combination plays an important role in the outcome of H. pylori associated diseases
models of infectious diseases show immunomodulatory effect of preparations on the basis of the interleukin-1 (IL-1) / ?Citokin? ltd., St. Petersburg, Russia./. To assess the effect of IL-1
Introduction: rhIL-1Ra is a recombinant form of the natural anti-inflammatory mediator, interleukin-1 receptor antagonist that competitively binds with type I receptors (IL-1RI). It inhibits effects ... other…
days post-surgery using the Confusion Assessment Method (CAM). Levels of Interleukin-1 Beta (IL-1β), Interleukin-6 (IL-6) and Tumor Necrosis Factor-α (TNF-α) were measured
sectional study investigated some inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and interleukin-10 (IL-10) concentrations
mutation TNFRSF1A. This represented the possibility to dampen inflammation with the selective blockade of interleukin-1. Using this rationale, we treated our patients. We suggest anakinra for the treatment